myelodysplastic syndromes (MDS) | Page 5 | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?

Author(s): 
Gorshein E, Weber UM, Gore S
Primary Author: 
Gorshein E
Journal Title: 
Expert Review of Hematology
Original Publication Date: 
Mar 2020

Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to

Bone Marrow Diseases: 

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

The purpose of this study is to determine whether the combination of pevonedistat and